Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from KRTX

GILD, BIIB, and KRTX: Biotech Buy, Hold, or Sell?

Rising healthcare needs, significant investments in R&D, robust drug pipeline, and use of advanced technology are some factors driving the biotech industry’s growth. Amid this favorable backdrop, let’s evaluate Gilead (GILD), Biogen (BIIB) and Karuna Therapeutics (KRTX) to determine the best investment action. Read more.

StockNews.com

Recap of Monday's Biotech Catalysts - End Of the Day Summary

Kodiak Sciences Inc. (NASDAQ:KOD) announced positive topline results its BEACON Phase 3 study of tarcocimab tedromer (KSI-301; tarcocimab) in patients with macular edema due to retinal vein occlusion. Kodiak shares traded in a range of $10.02 to $11.79 on a day volume of 4.05 million shares, closed regular trading session…

Benzinga

Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness

Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT for psychosis in Alzheimer's disease.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial

According to an SEC filing, Karuna Therapeutics Inc (NASDAQ:KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia. The Company had expected topline data from the EMERGENT-3 trial in 2H of 2022. At this time, the escalating conflict in Ukraine…

Benzinga

People

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.